CJC-1295 “no DAC” usually means Modified GRF 1-29, a short-acting growth hormone-releasing hormone (GHRH) analog often discussed with ipamorelin, a ghrelin-receptor growth hormone secretagogue 1, 3. Human research shows hormone signaling effects, not proven improvements in muscle, fat loss, recovery, sleep, or longevity 1, 3, 5. Neither peptide is FDA-approved for these uses 5, 6, 9.
Wondering if sermorelin is right for you? Take the 3-min clinical quiz.
See if you qualify →What is CJC-1295 no DAC with ipamorelin?
CJC-1295 no DAC with ipamorelin is an often-discussed pairing of peptides that signal through the growth hormone axis 1, 3. The important detail is that “no DAC” and CJC-1295 with DAC are not interchangeable names: the best-known CJC-1295 studies evaluated the longer-acting DAC-modified compound over several days of hormone monitoring 1.
Why “CJC-1295 no DAC” usually means Modified GRF 1-29
CJC-1295 is a synthetic GHRH analog 1. GHRH is a natural signal that acts on somatotroph cells in the pituitary gland and contributes to GH release 1, 4. DAC stands for Drug Affinity Complex, a modification designed to lengthen exposure through albumin binding 1. In online peptide discussions, “CJC-1295 no DAC” usually means Modified GRF 1-29, a shorter-acting GHRH analog rather than the exact DAC-containing peptide used in the landmark CJC-1295 trials.
What ipamorelin acetate is
Ipamorelin acetate is a growth hormone secretagogue 3. It acts at the growth hormone secretagogue receptor, called GHS-R1a, which is part of the ghrelin-signaling pathway 3. A human volunteer study found pharmacologic GH release after ipamorelin exposure, but it did not test whether ipamorelin improves aging, muscle mass, body fat, or recovery in healthy adults 3.
Why these peptides are commonly discussed as a stack
The proposed rationale is that a GHRH analog and a ghrelin-receptor agonist act through different signals that converge at the pituitary 1, 3. That is a mechanism, not proof of clinical synergy. There are no strong human outcome trials showing that the specific Modified GRF 1-29 plus ipamorelin combination produces better results than either compound alone 5, 6, 9.
How are CJC-1295 with DAC and no DAC different?
CJC-1295 with DAC is designed to be longer acting, while CJC-1295 no DAC usually describes shorter-acting Modified GRF 1-29 1. The distinction matters because the long-acting DAC form is the version evaluated in the most cited CJC-1295 human studies 1, 4.
| Feature | CJC-1295 with DAC | CJC-1295 no DAC / Modified GRF 1-29 | Ipamorelin |
|---|---|---|---|
| Main pathway | GHRH receptor signaling 1 | GHRH receptor signaling 1 | Ghrelin receptor / GHS-R1a signaling 3 |
| General exposure concept | Longer-acting GHRH analog 1 | Shorter-acting GHRH analog 1 | Growth hormone secretagogue 3 |
| Best human evidence | Healthy-adult GH and IGF-1 biomarker studies 1, 4 | Less direct human evidence under this common online name 1, 4 | Human pharmacology research and a postoperative ileus trial 2, 3 |
| What is not established | Muscle gain, fat loss, recovery, sleep, or longevity outcomes 1, 5 | Muscle gain, fat loss, recovery, sleep, or longevity outcomes 5, 6 | Muscle gain, fat loss, recovery, sleep, or longevity outcomes 2, 3, 5 |
| FDA status | Not FDA-approved for these uses 5, 6, 9 | Not FDA-approved for these uses 5, 6, 9 | Not FDA-approved for these uses 5, 6, 9 |
What DAC means
The Drug Affinity Complex was designed to make CJC-1295 bind albumin, a common protein in blood, and remain in circulation longer 1. A different duration of exposure can mean a different hormone pattern 1, 4. It does not, by itself, show that one version is more effective or safer for a wellness goal 5, 6.
Why naming matters before comparing studies or products
A study of CJC-1295 with DAC should not be presented as proof for a product labeled “no DAC.” Vague labels make it hard to know whether a product matches a compound used in published research. Our detailed guide to CJC-1295 no DAC explains this naming problem further.
How is ipamorelin different from CJC-1295?
Ipamorelin works through the ghrelin receptor, while CJC-1295 and Modified GRF 1-29 work through the GHRH receptor 1, 3. Both pathways can influence GH release, but the available human studies focus on hormone biomarkers and pharmacology, not broad wellness outcomes 2, 3.
GHRH receptor signaling versus ghrelin receptor signaling
GHRH analogs signal through the GHRH receptor on pituitary somatotroph cells 1, 4. Ipamorelin signals through GHS-R1a, the growth hormone secretagogue receptor 3. In plain language, they act through different biological signals that can both affect GH release 1, 3.
Growth hormone pulses and IGF-1
GH is normally released in pulses 4. GH signaling can influence IGF-1, a blood marker often used to assess GH-axis activity 1. In a human clinical study of long-acting CJC-1295, pulsatile GH secretion persisted during continuous stimulation 4. That finding describes hormone physiology; it does not establish long-term health or performance benefits.
What does the research actually show?
CJC-1295 and ipamorelin have limited human research, but the strongest findings are narrower than many online claims suggest. The main studies measured GH, IGF-1, drug pharmacology, or a surgical recovery question over limited study periods 1, 2, 3.
CJC-1295 with DAC in healthy adults
In a randomized study of healthy adults, CJC-1295 with DAC produced prolonged, dose-dependent increases in GH and IGF-1 1. A separate human study found that GH pulses persisted during continuous stimulation with the long-acting analog 4. These were useful studies of the GH axis, but they did not prove improvements in body composition, sleep, injury recovery, or lifespan.
Ipamorelin in human volunteers
A human pharmacokinetic-pharmacodynamic study showed that ipamorelin can stimulate GH release 3. This supports the basic mechanism. It does not define long-term safety or demonstrate that healthy people will gain muscle, lose fat, or experience better recovery.
Ipamorelin in postoperative ileus research
A randomized proof-of-concept study evaluated ipamorelin for postoperative ileus in people having bowel resection 2. Postoperative ileus is a temporary slowing of bowel function after surgery 2. This is a distinct medical research setting and should not be used as evidence for bodybuilding, anti-aging, or general wellness use.
What the evidence does not prove
There is no strong human evidence that the CJC-1295 no DAC plus ipamorelin stack builds muscle, produces meaningful fat loss, improves recovery, or extends life 5, 6, 9. A registered Phase 2 study of CJC-1295 in HIV-associated visceral obesity was terminated, which does not provide completed outcome evidence for that use 7. Recent clinical reviews also describe injectable peptide therapy as an evolving field with important evidence and regulatory limits 5, 6.
3-min quiz
Discuss a clinician-reviewed sermorelin option
Chia does not offer CJC-1295, Modified GRF 1-29, or ipamorelin. If you want to discuss sermorelin, a related but distinct GHRH-pathway peptide, an online evaluation can help determine whether it is clinically appropriate. A prescription requires medical review and is not guaranteed. Compounded medications are not FDA-approved.
Should you choose CJC-1295 with DAC or no DAC?
Choosing between CJC-1295 with DAC and no DAC is not a do-it-yourself dosing decision. The formulations have different exposure concepts, product names may be used inconsistently, and there are no strong stack outcome trials to guide a personal choice 1, 5, 6, 9.
Theoretical tradeoffs: sustained exposure versus shorter pulses
The DAC-modified compound was designed for sustained exposure, while Modified GRF 1-29 is generally described as shorter acting 1. Neither “longer acting” nor “shorter acting” automatically means better or safer. A clinician needs to consider your health history, medications, symptoms, and the limits of available evidence.
Why product labels and online stack names can be misleading
Online products sometimes use “CJC-1295” without clearly identifying whether they mean a DAC-modified compound or Modified GRF 1-29. Without that detail, it is not possible to reliably connect a product to the human evidence. For a broader comparison, see CJC-1295, ipamorelin, and sermorelin.
What are the downsides and safety concerns?
Growth-hormone peptides affect a real hormone system, and uncertainty is a major safety concern. The main issues are limited long-term data, unclear product identity, potential hormone-related effects, and quality risks from research-use-only products 1, 3, 5.
What human studies can and cannot tell us about safety
The available CJC-1295 and ipamorelin studies were not designed to establish long-term safety for aging, fitness, or wellness use 1, 2, 3. A clinician should carefully review conditions that affect the endocrine system, glucose regulation, pregnancy status, cancer history, and other medicines before considering any treatment that affects GH signaling.
FDA concerns about ipamorelin acetate compounding
FDA places nominated bulk drug substances in Category 2 when it identifies potential significant safety risks while evaluating them under its interim compounding policies 8. FDA’s current page lists ipamorelin acetate in Category 2 for 503B outsourcing facilities and identifies concerns including limited safety information for some routes and possible immunogenicity risks related to peptide aggregation or peptide-related impurities 8.
Risks of research-use-only peptides and group buys
Research-use-only products are not medications for human use. A vial marketed for laboratory research does not provide a prescription pathway, clinical screening, or reliable assurance of identity, sterility, storage, and chain of custody. Read our guides to peptide group buys and peptide side effects before relying on online claims.
How long does CJC-1295 ipamorelin take to work?
For CJC-1295 no DAC plus ipamorelin, there is no evidence-based timeline for visible results because the combination lacks strong human outcome trials 5, 6, 9. Changes in GH or IGF-1 biomarkers are not the same as proven changes in muscle, fat, recovery, sleep, or longevity 1, 3.
Why hormone biomarkers are not visible results
A biomarker can help researchers understand a pathway, but it cannot prove a person will have a meaningful clinical outcome. The CJC-1295 trials measured GH and IGF-1, while the ipamorelin volunteer study measured GH release and pharmacology 1, 3. Neither type of finding creates a proven “results” timeline for the stack.
What to discuss with a licensed clinician
Instead of relying on before-and-after posts, discuss the specific goal, relevant diagnosis, medical history, medication list, risks, and a plan for follow-up with a licensed clinician. A careful evaluation should be more than selecting a peptide name from a menu.
How does this compare with sermorelin at Chia?
Sermorelin is a related but distinct GHRH-pathway peptide. Chia does not offer CJC-1295, Modified GRF 1-29, or ipamorelin; we offer sermorelin as an injection, nasal spray, or tablet after licensed-provider review when clinically appropriate. Compounded medications are not FDA-approved.
Sermorelin is not the same compound as CJC-1295, and it is not ipamorelin. Like CJC-1295, sermorelin relates to the GHRH pathway; ipamorelin acts through the ghrelin receptor 1, 3. Our comparison of sermorelin vs. CJC-1295 no DAC can help you understand the distinction.
| Chia option | Available forms | Current starting price | How access works |
|---|---|---|---|
| Sermorelin | Injection, nasal spray, tablets | Injection plans from $140/mo; nasal spray plans from $179/mo | Online questionnaire, licensed US provider review, provider-guided dosing when prescribed, US 503A pharmacy compounding, and home delivery |
| Weight + Muscle | Sermorelin injection plus choice of GLP-1 | Plans from $329/mo | Online evaluation and prescription only when clinically appropriate |
At Chia, you begin with a short online health questionnaire. A licensed US provider reviews your history and goals, then prescribes only where clinically appropriate. If prescribed, medication is compounded in the US by a state-licensed 503A pharmacy, shipped to your door, and dosing is guided over time through the patient portal.
What should you ask a clinician before using any growth-hormone peptide?
Before considering any growth-hormone peptide, ask about the health problem being addressed, the evidence for that goal, and how you would be monitored over the first months of care. The discussion should not start and end with a product label.
- What diagnosis or goal are we trying to address, and what evidence supports this approach?
- What medical history, medications, and baseline information need review first?
- What symptoms or safety concerns would mean this treatment is not appropriate?
- How would follow-up, side-effect reporting, and any needed laboratory monitoring work?
- Is this a prescription medication from a state-licensed pharmacy, or a research-use-only product that should not be used by people?
- What is the plan if symptoms change, side effects occur, or the treatment does not fit my goals?
If an AI agent is helping organize care, DoctorMCP at mcp.chia.health can route a request into Chia’s licensed-provider evaluation flow. It is not an automated prescription pathway and does not guarantee that a prescription will be issued.
FAQ
No. Sermorelin and CJC-1295 are distinct compounds, though both are related to GHRH-pathway signaling 1. Chia offers sermorelin after licensed-provider review, but does not offer CJC-1295, Modified GRF 1-29, or ipamorelin.
Some care can begin online through a licensed medical evaluation and an appropriate pharmacy pathway. Research-use-only peptide products should not be treated as medications for human use. At Chia, sermorelin starts with an online questionnaire and provider review, and a prescription is never guaranteed.
3-min quiz
Start a clinician-reviewed sermorelin evaluation
Chia does not offer CJC-1295, Modified GRF 1-29, or ipamorelin. You can discuss sermorelin or the Weight + Muscle protocol with a licensed provider through an online evaluation. A prescription requires medical review and is not guaranteed. Compounded medications are not FDA-approved.
References
- 1.Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology and Metabolism. 2006.
- 2.Beck DE, Sweeney WB, McCarter MD, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease. 2014.
- 3.Gobburu JV, Agersø H, Jusko WJ, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research. 1999.
- 4.Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of Clinical Endocrinology and Metabolism. 2006.
- 5.Mayfield CK, Bolia IK, Feingold CL, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American Journal of Sports Medicine. 2026.
- 6.Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews. 2026.
- 7.ClinicalTrials.gov. A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity (NCT00267527). U.S. National Library of Medicine. 2026.
- 8.U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. 2026.
- 9.Superpower. CJC-1295 and Ipamorelin: Mechanism & Research. 2026.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if sermorelin is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.



